About Event
Digital Pathology & AI in GI & Fibrotic Diseases Summit: The First Industry Forum to Transform Pathological Assessments of Tissues, Beyond Oncology
This 3-day summit will bring together a wealth of knowledge on using machine learning and artificial intelligence to integrate histology, molecular pathology, and clinical data.
For the first-time ever, this meeting aims to help scientists, pathologists and entrepreneurs make significant contributions to the area of digital pathology by offering high-quality instructional and informational resources, promoting user-friendly digital pathology and tissue image analysis solutions.
Join 60+ industry leaders in leveraging digital pathology to standardize understanding of efficacy, segment heterogeneous patient populations, and de-risk clinical development across gastrointestinal, inflammatory, and fibrotic diseases.
Join Your Peers to:
Examine the latest advancements in image quality, scanning speed, pattern recognition and 3D imaging to overcome challenges in image analysis standardization with Takeda and Columbia University
Delve deeper into implementing AI–enabling workflow and AI integration in addition to enhanced cloud computing and storage solutions with Bristol Myers Squibb and University of Michigan to improve prediction performance
Take next generation sequencing, biomarker analysis and digital biobanking to the clinic with Novartis and AstraZeneca by understanding and integrating computational pathology
Move beyond non-standardized assessment of biopsies with Alentis Therapeutics and University of Duke to standardize the regulatory endpoints and establish quantitative efficacy for fibrotic and GI diseases
Interrogate heterogeneous patient presentation and reclassify patient subpopulations through ML image analysis with AstraZeneca to gain better understanding of disease heterogeneity
Who Will You Meet?
This summit is uniquely positioned to provide strategic insight - join 60+ industry pioneers including Digital Pathologists, Image Analysts, and experts in Fibrosis and gastrointestinal diseases from Novartis, AstraZeneca, Takeda, Bristol Myers Squibb and many more to advance application of digital pathology in drug development and de-risk the pathway to regulatory approval.
Testimonials from the Hanson Wade CVRM Series:
‘Amazing presentations from relevant pharma, biotech, FDA and academia with good discussions. Very good to see the combination of clinical and pre-clinical and many different companies involved' – AstraZeneca
'Well organized conference with excellent speakers on hot topics in renal diseases' - AceLink Therapeutics
'This was an excellent conference to get an update on the current therapies, clinical development challenges and novel approaches to treating obesity and NASH' - Mitotherapeutix